Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 May;1822(5):625-30.
doi: 10.1016/j.bbadis.2011.10.003. Epub 2011 Oct 12.

Elevation of glutathione as a therapeutic strategy in Alzheimer disease

Affiliations
Review

Elevation of glutathione as a therapeutic strategy in Alzheimer disease

Chava B Pocernich et al. Biochim Biophys Acta. 2012 May.

Abstract

Oxidative stress has been associated with the onset and progression of mild cognitive impairment (MCI) and Alzheimer disease (AD). AD and MCI brain and plasma display extensive oxidative stress as indexed by protein oxidation, lipid peroxidation, free radical formation, DNA oxidation, and decreased antioxidants. The most abundant endogenous antioxidant, glutathione, plays a significant role in combating oxidative stress. The ratio of oxidized to reduced glutathione is utilized as a measure of intensity of oxidative stress. Antioxidants have long been considered as an approach to slow down AD progression. In this review, we focus on the elevation on glutathione through N-acetyl-cysteine (NAC) and γ-glutamylcysteine ethyl ester (GCEE) as a potential therapeutic approach for Alzheimer disease. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Recycling of glutathione (GSH) and oxidized glutathione (GSSG).
Figure 2
Figure 2
Synthesis of Glutathione
Figure 3
Figure 3
Structure of N-acetyl-L-cysteine (NAC).
Figure 4
Figure 4
A) Aβ produces ROS that eventually leads to the depletion of antioxidants and oxidative stress in Alzheimer disease. The increased oxidation induces apoptotic signaling pathways and inflammation in astrocytes. Astrocytes release toxic inflammatory mediators and free radicals, accelerating activation of microglia and neurodegeneration, connecting the cycle of negative events perpetuating AD. B) NAC down-regulates APP gene transcription, resulting in undetectable levels of APP mRNA. Thus, since less Aβ is transcribed, fewer free radicals are produced by Aβ. NAC increases antioxidant levels of glutathione and reacts with ROS preventing oxidative stress. The decreased oxidation in the cells induces anti-apoptotic signaling pathways and prevents inflammation of the cell. NAC directly inhibits inflammatory factor NF-κB and blocks production of nitric oxide from inducible nitric oxide synthase and inflammatory cytokines.
Figure 4
Figure 4
A) Aβ produces ROS that eventually leads to the depletion of antioxidants and oxidative stress in Alzheimer disease. The increased oxidation induces apoptotic signaling pathways and inflammation in astrocytes. Astrocytes release toxic inflammatory mediators and free radicals, accelerating activation of microglia and neurodegeneration, connecting the cycle of negative events perpetuating AD. B) NAC down-regulates APP gene transcription, resulting in undetectable levels of APP mRNA. Thus, since less Aβ is transcribed, fewer free radicals are produced by Aβ. NAC increases antioxidant levels of glutathione and reacts with ROS preventing oxidative stress. The decreased oxidation in the cells induces anti-apoptotic signaling pathways and prevents inflammation of the cell. NAC directly inhibits inflammatory factor NF-κB and blocks production of nitric oxide from inducible nitric oxide synthase and inflammatory cytokines.
Figure 5
Figure 5
Structure of γ-glutymylcysteine ethyl ester (GCEE).

Similar articles

Cited by

References

    1. Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis. 2001;3:75–80. - PubMed
    1. Dahlgren KN, Manelli AM, Stine WB, Jr., Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J Biol Chem. 2002;277:32046–32053. - PubMed
    1. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267–298. - PubMed
    1. Fawzi NL, Okabe Y, Yap EH, Head-Gordon T. Determining the critical nucleus and mechanism of fibril elongation of the Alzheimer's Abeta(1–40) peptide. J Mol Biol. 2007;365:535–550. - PMC - PubMed
    1. Walsh DM, Hartley DM, Condron MM, Selkoe DJ, Teplow DB. In vitro studies of amyloid β-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease. Biochem J. 2001;355:869–877. - PMC - PubMed

Publication types